Abstract
Purpose
There is ongoing debate about whether tamoxifen for breast cancer is associated with a risk of endometrial cancer in Japanese women. We conducted a study to investigate this further.
Methods
We conducted a retrospective hospital-based cohort study. A total of 674 consecutive patients underwent surgery for primary breast cancer between January 1989 and December 1998. By December 2003, endometrial cancers had been diagnosed in six of these patients. Based on medical records, we evaluated the potential risk factors for endometrial cancer, including age, menopausal status, obesity, parity, diabetes mellitus, hypertension, and tamoxifen. The 674 patients were divided into three groups based on the cumulative duration of tamoxifen use (A, <2 years vs B, 2–5 years vs C, >5 years). To examine the relationships between endometrial cancer and tamoxifen (and other factors), the hazards ratio (HR), 95% confidence interval (CI), and two-sided P value for endometrial cancer associated with each variable were calculated by the Cox regression method.
Results
Endometrial cancer was found in 1/318 (0.31%) patients in group A, 3/247 in group B, and 2/109 in group C. In a multivariate analysis no variable was significant, but tamoxifen use for longer than 5 years (group C) was closely correlated with endometrial cancer (HR = 7.92, CI = 0.69–90.89, P = 0.096).
Conclusion
Although our data did not reach significance, they support a link between long-term tamoxifen and the development of endometrial cancer in Japanese women with breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
B Fisher JP Costantino CK Redmond ER Fisher DL Wickerham WM Cronin (1994) ArticleTitleEndometrial cancer in tamoxifen-treated breast cancer patients: findings from the national surgical adjuvant breast and bowel project (NSABP) B-14 J Natl Cancer Inst 86 527–37 Occurrence Handle8133536 Occurrence Handle1:STN:280:DyaK2c7otVCjug%3D%3D
LE Rutqvist H Johansson T Signomklao U Johansson T Fornander N Wilking (1995) ArticleTitleAdjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies J Natl Cancer Inst 87 645–51 Occurrence Handle7752269 Occurrence Handle1:STN:280:DyaK2M3ntFKqtQ%3D%3D
FE van Leeuwen J Benraadt JW Coebergh LA Kiemeney CH Gimbrere R Otter et al. (1994) ArticleTitleRisk of endometrial cancer after tamoxifen treatment of breast cancer Lancet 343 448–52 Occurrence Handle7905955 Occurrence Handle1:STN:280:DyaK2c7kt1Chug%3D%3D
Y Matsuyama T Tominaga Y Nomura H Koyama M Kimura M Sano et al. (2000) ArticleTitleSecond cancers after adjuvant tamoxifen therapy for breast cancer in Japan Ann Oncol 11 1537–43 Occurrence Handle11205460 Occurrence Handle10.1023/A:1008383804811 Occurrence Handle1:STN:280:DC%2BD3M7pt1KitQ%3D%3D
K Katase Y Sugiyama K Hasumi M Yoshimoto F Kasumi (1998) ArticleTitleThe incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma Cancer 82 1698–703 Occurrence Handle9576291 Occurrence Handle10.1002/(SICI)1097-0142(19980501)82:9<1698::AID-CNCR16>3.0.CO;2-# Occurrence Handle1:STN:280:DyaK1c3jsFyhtg%3D%3D
FIGO News (1989) ArticleTitleCorpus cancer staging Int J Gynecol Obstet 28 189–93
SG Silverberg RJ Kurman (1992) Tumors of the uterine corpus and gestational trophoblastic disease J Rosai LH Sobin (Eds) Atlas of tumor pathology. 3rd series Armed Forces Institute of Pathology Washington, DC 47–89
T Fornander LE Rutqvist B Cedermark U Glas A Mattsson C Silfversward et al. (1989) ArticleTitleAdjuvant tamoxifen in early breast cancer: occurrence of new primary cancers Lancet 1 117–20 Occurrence Handle2563046 Occurrence Handle1:STN:280:DyaL1M%2Fps1WgsQ%3D%3D
L Bernstein D Deapen JR Cerhan SM Schwartz J Liff E McGann-Maloney et al. (1999) ArticleTitleTamoxifen therapy for breast cancer and endometrial cancer risk J Natl Cancer Inst 91 1654–62 Occurrence Handle10511593 Occurrence Handle10.1093/jnci/91.19.1654 Occurrence Handle1:CAS:528:DyaK1MXmvVynurs%3D
L Bergman ML Beelen MP Gallee H Hollema J Benraadt FE van Leeuwen (2000) ArticleTitleRisk and prognosis of endometrial cancer after tamoxifen for breast cancer Lancet 356 881–7 Occurrence Handle11036892 Occurrence Handle10.1016/S0140-6736(00)02677-5 Occurrence Handle1:CAS:528:DC%2BD3cXmslKlsLY%3D
H Mignotte C Lasset V Bonadona A Lesur E Luporsi JF Rodier et al. (1998) ArticleTitleIatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study Int J Cancer 76 325–30 Occurrence Handle9579567 Occurrence Handle10.1002/(SICI)1097-0215(19980504)76:3<325::AID-IJC7>3.0.CO;2-X Occurrence Handle1:CAS:528:DyaK1cXjtVOrur4%3D
SM Ismail (1994) ArticleTitlePathology of endometrium treated with tamoxifen J Clin Pathol 47 827–33 Occurrence Handle7962652 Occurrence Handle1:STN:280:DyaK2M%2FltFKltA%3D%3D
L Deligdisch T Kalir CJ Cohen M de Latour GL Bouedec F Penault-Llorca (1999) ArticleTitleEndometrial histopathology in 700 patients treated with tamoxifen for breast cancer Gynecol Oncol 78 181–6
EG Silva CS Tornos M Follen-Mitchell (1994) ArticleTitleMalignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen Int J Gynecol Pathol 13 248–58 Occurrence Handle7928058 Occurrence Handle1:STN:280:DyaK2M%2FhtlSitg%3D%3D Occurrence Handle10.1097/00004347-199407000-00009
K Yamazawa H Matsui H Ishikura K Seki S Sekiya (2002) ArticleTitleClear cell adenocarcinoma within a tamoxifen-related polyp Acta Obstet Gynecol Scand 81 985–7 Occurrence Handle12366493 Occurrence Handle10.1034/j.1600-0412.2002.811016.x
Report of the Oncologic Committee (in Japanese). Nippon Sanfujinnka Gakkaisi 2001;53:788–800
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yamazawa, K., Miyazawa, Y., Suzuki, M. et al. Tamoxifen and the Risk of Endometrial Cancer in Japanese Women with Breast Cancer. Surg Today 36, 41–46 (2006). https://doi.org/10.1007/s00595-004-3126-5
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00595-004-3126-5